BLUESTAR GENOMICS INC. (ClearNote Health)
History
| Year | Detail |
|---|---|
| 2016 | Quake co-founded Bluestar Genomics to develop advanced liquid biopsy tests to address the deadliest cancers by detecting cancer signals earlier than existing methods. |
| 2019 | Bluestar Genomics presented new data demonstrating feasibility of a novel blood test for earlier detection and classification of multiple cancers. |
| 2020 | Bluestar Genomics and the University of Chicago collaboratively published the first complete genome map of key biomarkers for the detection of cancer and other diseases. |
| 2022 | At the American Pancreatic Association's annual meeting, the company launched a physician experience program to bring its pancreatic cancer detection test into clinical use based on positive validation study results reported. |
| Bluestar Genomics Rebrands as ClearNote Health. | |
| 2023 | ClearNote Health collaborated with Bayer to investigate Drug Treatment Response (DTR) by Liquid Biopsy in Prostate Cancer. |